Hello! You're looking at a policy document report on Overton

We track government policy, guidelines, think tank research, working papers and more to help our customers see the impact and influence of their work.

If you fund, produce or manage research or work to influence policy, we'd love to talk. Learn more on our homepage.

Recognized names mentioned in this document

Overton only tracks names from certain institutions. Names must have been cited in at least one policy document and their corresponding affiliation has to be found nearby - you can find more details on the help page.

Everything cited by this document (explore the cited scholarly articles)

Journal of Clinical Epidemiology (Elsevier BV)
Gordon H. Guyatt et al. 2011
Journal of Clinical Epidemiology 64 (2011) 395e400 http://dx.doi.org/10.1016/j.jclinepi.2010.09.012
0895-4356/$ - see front matter Ă“ 2011 Elsevier Inc. All rights reserved. doi: 10.1016/j.jclinepi.2010.09.012
http://dx.doi.org/10.1016/j.jclinepi.2010.09.012
aspirin that enrolled patients from both populations suggested [2]), a single estimate across the range of patients and interventions will not well serve the decision-making needs of patients and clinicians.
On page 2
[2] CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1997;348:1329e39.
The Lancet (Elsevier BV)
John Eikelboom et al. 2008
For example, the European Society of Cardiology makes recommendations for use of anticoagulants in patients with non-ST elevation acute coronary syndromes receiving conservative (noninvasive) management [5].
On page 2
[5] Eikelboom J, Guyatt G, Hirsh J. Guidelines for anticoagulant use in acute coronary syndromes. Lancet 2008;371:1559e61.
JAMA (American Medical Association (AMA))
Heike A. Bischoff-Ferrari et al. 2005
Systematic reviews may even focus on a single outcome (e.g., the impact of statins on stroke [10] or vitamin D on nonvertebral fractures [11]).
On page 3
Bischoff-Ferrari HA, Willett WC, Wong JB, Giovannucci E, Dietrich T, Dawson-Hughes B.
On page 6
[11] Bischoff-Ferrari HA, Willett WC, Wong JB, Giovannucci E, Dietrich T, Dawson-Hughes B. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA 2005;293:2257e64.
The Lancet (Elsevier BV)
Victor M Montori et al. 2007
For example, in type 2 diabetes, clinical trials have failed to adequately address the long-term impact of alternative management strategies on diabetic complications of micro- and macrovascular disease, and neuropathic complications [12]; this omission is unlikely to be corrected in the near future [13].
On page 4
[12] Montori VM, Gandhi GY, Guyatt GH. Patient-important outcomes in diabetesdtime for consensus. Lancet 2007;370:1104e6.
JAMA (American Medical Association (AMA))
Gunjan Y. Gandhi 2008
For example, in type 2 diabetes, clinical trials have failed to adequately address the long-term impact of alternative management strategies on diabetic complications of micro- and macrovascular disease, and neuropathic complications [12]; this omission is unlikely to be corrected in the near future [13].
On page 4
Gandhi GY, Murad MH, Fujiyoshi A, Mullan RJ, Flynn DN, Elamin MB, et al. Patient-important outcomes in registered diabetes trials.
On page 6
[13] Gandhi GY, Murad MH, Fujiyoshi A, Mullan RJ, Flynn DN, Elamin MB, et al. Patient-important outcomes in registered diabetes trials. JAMA 2008;299:2543e9.
JAMA (American Medical Association (AMA))
Karen E. Lasser 2002
G.H. Guyatt et al. / Journal of Clinical Epidemiology 64 (2011) 395e400 a quarter of a century, important unexpected toxicity has emerged in approximately 20% of the U.S. Food and Drug Administrationeapproved drugs [15].
On page 6
Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH.
On page 6
[15] Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH. Timing of new black box warnings and withdrawals for prescription medications. JAMA 2002;287:2215e20.
Diabetes Care (American Diabetes Association)
Samantha L. Bowker et al. 2006
For instance, an observational study found a previously unsuspected association between sulfonylurea use and cancer-related mortality [16].
On page 6
[16] Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylurea or insulin. Diabetes Care 2006;29:254e8.